Sergiusz Jóźwiak1, Krzysztof Sadowski2, Katarzyna Kotulska3, Robert A Schwartz4. 1. Department of Pediatric Neurology, Warsaw Medical University, Warsaw, Poland; Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland. 2. Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland. Electronic address: sadowski.ks@gmail.com. 3. Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland. 4. Department of Dermatology, Rutgers University, New Jersey Medical School, Newark, New Jersey; Department of Pediatrics, Rutgers University, New Jersey Medical School, Newark, New Jersey; Department of Preventive Medicine and Community Health, Rutgers University, New Jersey Medical School, Newark, New Jersey; Rutgers University School of Public Affairs and Administration, Newark, New Jersey.
Abstract
BACKGROUND: Tuberous sclerosis complex is a genetically determined multisystem disorder that may affect almost any human organ. The discovery of the mammalian target of rapamycin (mTOR) pathway and its involvement in tuberous sclerosis complex-related pathology has led to the introduction of mTOR inhibitors into clinical practice. Topical administration of mTOR inhibitors for skin lesions related to tuberous sclerosis complex may represent a reasonable alternative for more invasive procedures. A growing number of patients have been described exhibiting positive therapeutic effects from the topical administration of these agents. The aim of this review was to systematically analyze available literature on the use of topical mTOR inhibitors to treat dermatologic lesions related to tuberous sclerosis complex. RESULTS: A comprehensive review of PubMed, Medscape, and Cochrane databases between 1995 and 2015 was performed to identify available studies describing topical use of mTOR inhibitors in individuals with tuberous sclerosis complex. In most studies, topical mTOR inhibitor application proved to be effective in the treatment of skin lesions related to tuberous sclerosis complex. Facial angiofibromas were the target lesions in most instances. Few studies reported clinical improvement of hypomelanotic macules. These drugs directly address the molecular defect related to tuberous sclerosis complex manifestations. CONCLUSIONS: Currently available clinical data suggest that topical application of mTOR inhibitors may be effective in the treatment of facial angiofibromas associated with tuberous sclerosis complex. Ongoing randomized clinical trials of topical mTOR inhibitors for TSC-related cutaneous lesions should add clarity to the role of these agents.
BACKGROUND:Tuberous sclerosis complex is a genetically determined multisystem disorder that may affect almost any human organ. The discovery of the mammalian target of rapamycin (mTOR) pathway and its involvement in tuberous sclerosis complex-related pathology has led to the introduction of mTOR inhibitors into clinical practice. Topical administration of mTOR inhibitors for skin lesions related to tuberous sclerosis complex may represent a reasonable alternative for more invasive procedures. A growing number of patients have been described exhibiting positive therapeutic effects from the topical administration of these agents. The aim of this review was to systematically analyze available literature on the use of topical mTOR inhibitors to treat dermatologic lesions related to tuberous sclerosis complex. RESULTS: A comprehensive review of PubMed, Medscape, and Cochrane databases between 1995 and 2015 was performed to identify available studies describing topical use of mTOR inhibitors in individuals with tuberous sclerosis complex. In most studies, topical mTOR inhibitor application proved to be effective in the treatment of skin lesions related to tuberous sclerosis complex. Facial angiofibromas were the target lesions in most instances. Few studies reported clinical improvement of hypomelanotic macules. These drugs directly address the molecular defect related to tuberous sclerosis complex manifestations. CONCLUSIONS: Currently available clinical data suggest that topical application of mTOR inhibitors may be effective in the treatment of facial angiofibromas associated with tuberous sclerosis complex. Ongoing randomized clinical trials of topical mTOR inhibitors for TSC-related cutaneous lesions should add clarity to the role of these agents.
Authors: David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham Journal: Cell Date: 2017-08-10 Impact factor: 41.582
Authors: Nathan A Dahl; Timothy Luebbert; Michele Loi; Ilana Neuberger; Michael H Handler; Bette Kay Kleinschmidt-DeMasters; Jean M Mulcahy Levy Journal: J Neuropathol Exp Neurol Date: 2017-06-01 Impact factor: 3.685
Authors: Mary Kay Koenig; Cynthia S Bell; Adelaide A Hebert; Joan Roberson; Joshua A Samuels; John M Slopis; Patti Tate; Hope Northrup Journal: JAMA Dermatol Date: 2018-07-01 Impact factor: 10.282
Authors: Nicholas M P Annear; Richard E Appleton; Zahabiyah Bassi; Rupesh Bhatt; Patrick F Bolton; Pamela Crawford; Alex Crowe; Maureen Tossi; Frances Elmslie; Eric Finlay; Daniel P Gale; Alex Henderson; Elizabeth A Jones; Simon R Johnson; Shelagh Joss; Larissa Kerecuk; Graham Lipkin; Patrick J Morrison; Finbar J O'Callaghan; Jill Cadwgan; Albert C M Ong; Julian R Sampson; Charles Shepherd; J Chris Kingswood Journal: Front Neurol Date: 2019-11-06 Impact factor: 4.003